Mirum Pharmaceuticals Inc

$18.44 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. It has commenced enrollment in the Phase III clinical trial in PFIC and also planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases and expect to initiate Phase II clinical trials. In addition to data from ongoing clinical trials of maralixibat.

Stock Analysis

last close $18.44
1-mo return -7%
3-mo return 0.5%
avg daily vol. 110.89T
52-week high 27.43
52-week low 14.05
market cap. $554M
forward pe -
annual div. -
roe -68.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 79.6%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist